目的 探寻黄柏八味片联合多沙唑嗪在慢性前列腺炎患者中的治疗价值。方法 回顾性选取2024年5月—2025年5月在华中科技大学同济医学院附属梨园医院入组的60例慢性前列腺炎病例，依据所采用治疗方式的差异分为对照组和治疗组，每组各30例。对照组口服甲磺酸多沙唑嗪缓释片，2 mg/次，1次/d。治疗组在对照组的基础上口服黄柏八味片，3片/次，3次/d。两组均连续治疗8周。对比治疗后两组患者临床疗效、症状缓解、前列腺情况、尿动力学。结果 治疗后，治疗组总有效率明显高于对照组（100.00% vs 76.67%，P＜0.05）。治疗后，两组NIH-CPSI、中医证候积分均明显低于治疗前（P＜0.05），且与对照组相比，治疗组治疗后NIH-CPSI、中医证候积分均显著更低（P＜0.05）。治疗后，两组前列腺体积、前列腺移行区体积和前列腺质地评分均显著低于治疗前（P＜0.05），且治疗后治疗组在前列腺体积、前列腺移行区体积的缩小及前列腺质地评分的降低方面均显著优于对照组（P＜0.05）。治疗后，两组最大尿流率、平均尿流率明显升高，而膀胱残余尿量明显降低（P＜0.05）；且与对照组相比，治疗组治疗后最大尿流率、平均尿流率和膀胱残余尿量改善更明显（P＜0.05）。结论 黄柏八味片联合多沙唑嗪能够显著增强慢性前列腺炎的临床疗效，促进前列腺功能恢复，并有效改善尿动力学相关指标。

Objective To explore the therapeutic value of Huangbai Bawei Tablets combined with doxazosin in treatment of chronic prostatitis. Methods A total of 60 cases of chronic prostatitis admitted to Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from May 2024 to May 2025 were retrospectively enrolled. According to different treatment methods, they were divided into control group and treatment group, with 30 cases in each group. The control group received oral Doxazosin Mesylate Extended Release Tablets, 2 mg once daily. On the basis of the control group, the treatment group was given oral Huangbai Bawei Tablets, 3 tablets each time, 3 times a day. Both groups were treated continuously for 8 weeks. Clinical efficacy, symptom relief, prostate status and urodynamics were compared between the two groups after treatment. Results After treatment, the total effective rate of the treatment group was significantly higher than that of the control group (100.00% vs 76.67%, P < 0.05). After treatment, the NIH-CPSI scores and TCM syndrome scores in both groups were significantly lower than those before treatment (P < 0.05). Compared with the control group, the treatment group showed significantly lower NIH-CPSI scores and TCM syndrome scores after treatment (P < 0.05). After treatment, the prostate volume, transitional zone volume, and prostate texture scores in both groups were significantly reduced compared with before treatment (P < 0.05). Moreover, the treatment group demonstrated significantly greater improvements in prostate volume reduction, transitional zone volume reduction, and prostate texture score reduction than the control group after treatment (P < 0.05). After treatment, both groups exhibited a significant increase in maximum urinary flow rate and average urinary flow rate, along with a significant decrease in post-void residual urine volume (P< 0.05). Compared with the control group, the treatment group showed significantly greater improvements in maximum urinary flow rate, average urinary flow rate, and post-void residual urine volume after treatment (P< 0.05). Conclusion The combination of Huangbai Bawei Tablets and doxazosin can significantly improve the clinical efficacy of chronic prostatitis, promote the recovery of prostate function, and effectively improve urodynamic parameters.

R983

湖北省自然科学基金项目（2023AFD020）